The estimated Net Worth of Joseph Walter Vazzano is at least $1.02 Milion dollars as of 25 April 2024. Mr. Vazzano owns over 5,608 units of Avenue Therapeutics Inc stock worth over $678,217 and over the last 6 years he sold ATXI stock worth over $84,384. In addition, he makes $258,779 as Chief Financial Officer a Principal Financial Officer and Corporate Secretary at Avenue Therapeutics Inc.
Sign up
Mr. Vazzano ATXI stock SEC Form 4 insiders trading
Joseph has made over 8 trades of the Avenue Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,608 units of ATXI stock worth $17,609 on 25 April 2024.
The largest trade he's ever made was selling 7,160 units of Avenue Therapeutics Inc stock on 15 September 2021 worth over $11,599. On average, Joseph trades about 1,308 units every 72 days since 2018. As of 25 April 2024 he still owns at least 233,868 units of Avenue Therapeutics Inc stock.
You can see the complete history of Mr. Vazzano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joseph Vazzano biography
Joseph Vazzano is Chief Financial Officer, Principal Financial Officer and Corporate Secretary of the Company. Mr. Vazzano joined the Company in August 2017 as our Vice President of Finance and Corporate Controller. Effective February 8, 2019, the Board appointed Mr. Vazzano as the Company’s Chief Financial Officer. Prior to joining Avenue, Mr. Vazzano served as Assistant Corporate Controller at Intercept Pharmaceuticals, Inc., a publicly-traded biotechnology company, which he joined in 2016. While at Intercept, Mr. Vazzano helped grow the finance and accounting department during Intercept’s transition from a development-stage company to a fully integrated commercial organization. Prior to joining Intercept, Mr. Vazzano served as the Assistant Controller at Pernix Therapeutics, a publicly-traded specialty pharmaceutical company, where he successfully built an accounting and finance team after the closure of the South Carolina office location. From 2010 to 2015, he held various roles of increasing responsibility in finance and accounting at NPS Pharmaceuticals, a publicly-traded biotechnology company acquired by Shire Pharmaceuticals in 2015. He began his professional career with KPMG, LLP, where he served as a senior auditor. Mr. Vazzano has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New Jersey.
What is the salary of Joseph Vazzano?
As the Chief Financial Officer a Principal Financial Officer and Corporate Secretary of Avenue Therapeutics Inc, the total compensation of Joseph Vazzano at Avenue Therapeutics Inc is $258,779. There are 2 executives at Avenue Therapeutics Inc getting paid more, with Lucy Lu having the highest compensation of $639,783.
How old is Joseph Vazzano?
Joseph Vazzano is 36, he's been the Chief Financial Officer a Principal Financial Officer and Corporate Secretary of Avenue Therapeutics Inc since 2019. There are 11 older and no younger executives at Avenue Therapeutics Inc. The oldest executive at Avenue Therapeutics Inc is Dr. Scott A. Reines M.D., Ph.D., 74, who is the Interim Chief Medical Officer.
What's Joseph Vazzano's mailing address?
Joseph's mailing address filed with the SEC is 2 Gansevoort St 9TH FLOOR, New York, NY 10014, USA.
Insiders trading at Avenue Therapeutics Inc
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss a Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.
What does Avenue Therapeutics Inc do?
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
What does Avenue Therapeutics Inc's logo look like?
Complete history of Mr. Vazzano stock trades at Abeona Therapeutics Inc a Avenue Therapeutics Inc
Avenue Therapeutics Inc executives and stock owners
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lucy Lu,
President, Chief Executive Officer, Director -
Dr. Xiaoqin Lu M.D.,
Pres, CEO & Director -
Joseph Vazzano,
Chief Financial Officer, Principal Financial Officer and Corporate Secretary -
Joseph Walter Vazzano,
CFO, Principal Financial Officer & Company Sec. -
Neil Herskowitz,
Independent Director -
Jay Kranzler,
Independent Director -
Thomas Moore,
Independent Director -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman -
Garrett Ingram,
Director -
Jaideep Gogtay,
Director -
Lindsay Rosenwald,
Executive Chairman of the Board -
Dr. Scott A. Reines M.D., Ph.D.,
Interim Chief Medical Officer -
Jeffrey Paley,
Director -
Akhtar Samad,
Director -
Scott Reines,
Interim Chief Medical Officer -
Michael S Weiss,
Director -
Curtis Gale Oltmans,
Director -
Pharmaceuticals, Inc. Inva Gen,
10% owner -
Robert L Davidow,
10% owner -
Biotech, Inc. Fortress,
10% owner -
David Jin,
Interim PFO and COO -
Faith L. Charles,
Director